Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:


Last Updated: June 29, 2022

Details for Patent: RE46965

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: RE46965
Title:Intermediates for the preparation of analogs of Halichondrin B
Abstract: The present invention provides macrocyclic compounds, synthesis of the same and intermediates thereto. Such compounds, and compositions thereof, are useful for treating or preventing proliferative disorders Formula (F-4). ##STR00001##
Inventor(s): Austad; Brian (Tewksbury, MA), Chase; Charles E. (Londonderry, NH), Fang; Francis G. (Andover, MA), Calkins; Trevor (Stoughton, WI), Lewis; Bryan M. (North Brunswick, NJ)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:13/924,892
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent RE46965

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE46965

PCT Information
PCT FiledJune 03, 2005PCT Application Number:PCT/US2005/019669
PCT Publication Date:December 15, 2005PCT Publication Number: WO2005/118565

International Family Members for US Patent RE46965

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005250487 See Plans and Pricing
Canada 2567984 See Plans and Pricing
Canada 2822994 See Plans and Pricing
Canada 2935786 See Plans and Pricing
Canada 3028453 See Plans and Pricing
China 101899026 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.